Treatment response assessment in glioblastoma with GRASP DCE-MRI

Key Points

• Treatment response in glioblastoma is assessed using GRASP DCE-MRI, which allows for detailed imaging insights.
• Significant alterations in imaging biomarkers were noted in 45 patients over six months, indicating response variabilities.
• Analysis employed GRASP DCE-MRI to examine the permeability and invasion metrics linked with tumor response.
• Findings highlight the need for improved therapy monitoring methods, moving towards personalized treatment strategies.